Clinical Trial

Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Graft-versus-host disease is a complication of allogeneic hematopoietic cell transplantation with high morbidity and mortality. The standard treatment is corticosteroids, and based on the response within 3 to 7 days, a second-line therapy is added, which is expensive and not easily accessible. The administration of human chorionic gonadotropin has shown therapeutic effectiveness in 50% of patients in reported clinical cases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-25.
Trial Details
NCT Number NCT06904599
Lead Sponsor Hospital Universitario Dr. Jose E. Gonzalez
Collaborators: Marisa Romero Martínez, Dr. José Carlos Jaime Perez, Dr. David Gómez Almaguer, Dra. Consuelo Mancias Guerra, Dr. Andrés Gómez de León, Dra. Olga Graciela Catú Rodríguez, Dra. Perla Colunga Pedraza, Dra. Michelle Morcos Sandino
Conditions Acute Graft Versus Host Disease
Enrollment 20 participants
Start Date 2025-02-01
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-03